Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics

Launched by ONCOHOST LTD. · Feb 9, 2023

Keywords

ClinConnect Summary

This clinical trial is looking to understand how certain biological factors in patients with Non-Small Cell Lung Cancer (a common type of lung cancer) can predict how well they will respond to immunotherapy, which is a type of treatment that helps the immune system fight cancer. Researchers will collect samples and health information from patients before and during their treatment to identify patterns that could help determine who is most likely to benefit from this kind of therapy.

To participate in this study, individuals must be at least 18 years old and able to give their consent to join the trial. They should have a good performance status, meaning they are generally well enough to engage in normal activities. However, patients with other active cancers or significant mental impairments that could affect their understanding of the study are not eligible. Those who join can expect to provide biological samples and share their health data, contributing to valuable research that aims to improve cancer treatment outcomes for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Provision of informed consent prior to any study-specific procedures.
• • Male or female aged at least 18 years.
• • ECOG PS - 0/1-2.
• Exclusion Criteria:
• • Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of treatment.
• • Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.